Investors

Press Releases

All Releases

View Summary Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Oct 20, 2014
PDF 17.0 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Oct 17, 2014
PDF 16.2 KB Add to Briefcase
View Summary Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year
Oct 16, 2014
PDF 10.5 KB Add to Briefcase
View Summary Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments
Oct 16, 2014
PDF 13.1 KB Add to Briefcase
View Summary Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014
Oct 15, 2014
PDF 6.8 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)
Oct 6, 2014
PDF 15.7 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
Sep 30, 2014
PDF 16.2 KB Add to Briefcase
View Summary Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Sep 22, 2014
PDF 14.6 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Sep 16, 2014
PDF 20.3 KB Add to Briefcase
View Summary Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion
Sep 4, 2014
PDF 17.6 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Aug 31, 2014
PDF 22.8 KB Add to Briefcase
View Summary Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Aug 25, 2014
PDF 20.1 KB Add to Briefcase
View Summary Regeneron Announces Upcoming 2014 Investor Conference Presentations
Aug 19, 2014
PDF 8.7 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Aug 11, 2014
PDF 17.6 KB Add to Briefcase
View Summary Regeneron Reports Second Quarter 2014 Financial and Operating Results
Aug 5, 2014
PDF 38.6 KB Add to Briefcase
View Summary Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Jul 30, 2014
PDF 15.9 KB Add to Briefcase
View Summary Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
Jul 30, 2014
PDF 19.5 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)
Jul 29, 2014
PDF 22.3 KB Add to Briefcase
View Summary Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
Jul 18, 2014
PDF 8.5 KB Add to Briefcase
View Summary Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Jul 18, 2014
PDF 21.2 KB Add to Briefcase
Showing 1-20 of 244 Page: 1 2 3 4 5 ... 13  Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)